Indications
Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma.
Composition
- Active substance
- vemurafenib
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Zelboraf
- Active substance
- vemurafenib
- ATC code
- L01EC01
- Therapeutic area
- Melanoma
- Marketing authorisation holder
- Roche Registration GmbH
- Status
- Authorised
- EU authorisation
- 17 Feb 2012